mRNA technologies are the next big therapeutic modality with RNA based vaccines looking to have a major impact due to their shorter manufacturing times and greater effectiveness. This proves to be of more importance in this time of COVID-19, with the necessity to get an effective vaccine to the market at speed while ensuring regulatory and quality compliance. As mRNA vaccines move through the clinic, we need to source cGMP facilities to safely bring these products to the market. We are working with clients today to bring these revolutionary medicines to the world. Contact us to discuss how we can support your teams to develop capacity for your clinical and commercial pipeline.

Project Profiles

• 

  Moderna Therapeutics, Clinical Manufacturing Facility

  DPS and TRIA (a DPS Group company) were engaged by Moderna to provide full EPCMV and architectural design services to complete its new 200,000 sf cGMP clinical manufacturing facility in Norwood, MA.

  Location: Massachusetts

  Sector: mRNA Vaccines

  Project details
• 

  Moderna Therapeutics, GMP Manufacturing Facility Retrofit

  Moderna is a leader in the development of messenger RNA therapeutics. The company recently acquired a 13,000 sf space to expand their existing operations.

  Location: Massachusetts

  Sector: mRNA Vaccines

  Project details